Revvity (NYSE:RVTY - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Monday, April 28th. Analysts expect the company to announce earnings of $0.95 per share and revenue of $662.30 million for the quarter. Revvity has set its FY 2025 guidance at 4.900-5.000 EPS.
Revvity (NYSE:RVTY - Get Free Report) last announced its quarterly earnings results on Friday, January 31st. The company reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same period last year, the company earned $1.25 EPS. On average, analysts expect Revvity to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.
Revvity Stock Down 0.9 %
Shares of NYSE RVTY traded down $0.83 during midday trading on Friday, hitting $94.30. 1,390,004 shares of the stock traded hands, compared to its average volume of 913,815. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. Revvity has a one year low of $88.53 and a one year high of $129.50. The business has a 50 day moving average price of $104.87 and a two-hundred day moving average price of $113.09. The company has a market cap of $11.33 billion, a PE ratio of 42.67, a P/E/G ratio of 3.82 and a beta of 1.07.
Revvity Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 8th. Shareholders of record on Friday, July 18th will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $0.28 annualized dividend and a yield of 0.30%. Revvity's payout ratio is 12.67%.
Insider Activity
In related news, insider Joel S. Goldberg sold 15,170 shares of the company's stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the completion of the sale, the insider now directly owns 33,400 shares in the company, valued at $4,232,782. This represents a 31.23 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.68% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on the stock. Sanford C. Bernstein downgraded shares of Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 target price for the company. in a research report on Friday, January 10th. Robert W. Baird cut their price target on Revvity from $141.00 to $127.00 and set an "outperform" rating for the company in a research note on Monday, April 21st. Raymond James reiterated an "outperform" rating and issued a $145.00 target price (up previously from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Wells Fargo & Company cut their price target on shares of Revvity from $130.00 to $102.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Finally, Barclays dropped their target price on shares of Revvity from $140.00 to $110.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $130.50.
Check Out Our Latest Stock Report on RVTY
About Revvity
(
Get Free Report)
Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
See Also
Before you consider Revvity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revvity wasn't on the list.
While Revvity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
